|
Enzon Pharmaceuticals, Inc. - Comparative Business Analysis Snapshot
Business Description
Enzon Pharmaceuticals, Inc.. The Group's principal activity is to develop, manufacture and sell human therapeutics for life-threatening diseases. The Group includes three segments: Product sale which manufactures markets and sells pharmaceutical products for patients with cancer and other life-threatening diseases. Royalties, a source of revenue which is derived from sales of marketed products from PEG-INTRON, PEGASYS and MACUGEN that utilize our proprietary technology. Contract Manufacturing, where we utilize a portion of our excess manufacturing capacity to provide contract manufacturing services for a number of injectable products, such as single- and dual-chamber vial filling and lipid Complex formulations. The Group's products include ABELCET, ADAGEN, DEPOCYT and ONCASPAR.
Competitor Analysis
This analysis compares Enzon Pharmaceuticals, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
